Zur Hauptnavigation wechseln Zur Suche wechseln Zum Hauptinhalt wechseln

Longitudinal and cross-sectional associations of myocardial stress markers with kidney function and chronic kidney disease in the BiomarCaRE project

Jie-Sheng Lin, Tanja Zeller, Wolfgang Koenig, Pekka Jousilahti, Frank Kee, Licia Iacoviello, Hugh Tunstall-Pedoe, Stefan Söderberg, Giancarlo Cesana, Luigi Palmieri, Veikko Salomaa, Julia de Man Lapidoth, Roberto De Ponti, Chiara Donfrancesco, Thiess Lorenz, Kari Kuulasmaa, Stefan Blankenberg, Annette Peters, Barbara Thorand

Abstract

Given the complex relationship between cardiovascular disease (CVD) and chronic kidney disease (CKD), CVD-related markers may serve as CKD biomarkers. We examined associations of three major CVD-markers [mid-regional pro-adrenomedullin (MR-proADM), MR-pro-atrial natriuretic peptide (MR-proANP), and N-terminal pro-B-type natriuretic peptide (NT-proBNP)] with CKD. Cross-sectional analyses included up to 61,830 participants, and longitudinal analyses (NT-proBNP only) 4205 individuals. Kidney function was assessed by estimated glomerular filtration rate (eGFR) using creatinine, cystatin C, or both (eGFRcr-cys). Markers were categorized into four groups. Cross-sectional analyses found that higher levels of all three markers were consistently associated with lower eGFR and higher CKD prevalence. For example, per 1 standard deviation (SD) increase in log-transformed NT-proBNP, corresponding to a 2.71-fold increase in the original concentration, was associated with -2.35 (-2.49, -2.21) ml/min/1.73m2 lower eGFRcr-cys, and the highest NT-proBNP group had a 5.72-fold higher odds of CKDcr-cys (eGFRcr-cys < 60 ml/min/1.73m2) compared with the lowest. Associations with eGFR were stronger among participants with CVD and diabetes. In longitudinal analyses, participants with higher baseline NT-proBNP had faster declines in eGFR, with a 10-year decline of -1.37 (-1.77, -0.98) ml/min/1.73m2 eGFRcr-cys per 1 SD increase, and higher CKD incidence. These findings suggest MR-proADM, MR-proANP, and NT-proBNP as CKD biomarkers.

OriginalspracheEnglisch
Aufsatznummer7488
ZeitschriftScientific Reports
Jahrgang16
Ausgabenummer1
ISSN2045-2322
PublikationsstatusVeröffentlicht - 23.02.2026

Fördermittel

Open Access funding enabled and organized by Projekt DEAL. The MORGAM Project has received funding from EU projects MORGAM (Biomed, BMH4-CT98-3183), GenomEUtwin (FP5, QLG2-CT-2002–01254), ENGAGE (FP7, HEALTH-F4-2007–201413), CHANCES (FP7, HEALTH-F3-2010–242244), BiomarCaRE (FP7, HEALTH-F2-2011–278913), euCanSHare (Horizon 2020, No. 825903) and AFFECT-EU (Horizon 2020, No. 847770); and Medical Research Council, London (G0601463, No. 80983: Biomarkers in the MORGAM Populations). This has supported central coordination, workshops and part of the activities of the MORGAM Data Centre, the MORGAM Laboratories and the MORGAM Participating Centres. The MONICA/KORA study was initiated and financed by the Helmholtz Zentrum München – German Research Center for Environmental Health, which is funded by the German Federal Ministry of Education and Research (BMBF) and by the State of Bavaria. Data collection in the MONICA/KORA study is done in cooperation with the University Hospital of Augsburg. Northern Sweden MONICA was funded by the county councils in Norr- and Västerbotten, Umeå University, Swedish Research Council and Swedish Heart and Lung Foundation. The funders had no role in study design, data collection, analysis, decision to publish, or preparation of the manuscript.

TrägerTrägernummer
Bundesministerium für Forschung, Technologie und Raumfahrt
ENGAGE
Deutsches Forschungszentrum für Gesundheit und Umwelt, Helmholtz Zentrum München
MORGAM Laboratories
Umeå Universitet
Hjärt-Lungfonden
Vetenskapsrådet
Horizon 2020825903
AFFECT-EU847770
Seventh Framework ProgrammeHEALTH-F4-2007–201413
CHANCESHEALTH-F3-2010–242244, HEALTH-F2-2011–278913
European CommissionQLG2-CT-2002–01254, BMH4-CT98-3183
Medical Research Council80983, G0601463

    UN SDGs

    Dieser Output leistet einen Beitrag zu folgendem(n) Ziel(en) für nachhaltige Entwicklung

    1. SDG 3 – Gesundheit und Wohlergehen
      SDG 3 – Gesundheit und Wohlergehen

    Fingerprint

    Untersuchen Sie die Forschungsthemen von „Longitudinal and cross-sectional associations of myocardial stress markers with kidney function and chronic kidney disease in the BiomarCaRE project“. Zusammen bilden sie einen einzigartigen Fingerprint.

    Zitieren